Bio-Path Holdings, Inc. (BPTH) News

Bio-Path Holdings, Inc. (BPTH): $4.10

-0.03 (-0.73%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BPTH to Watchlist
Sign Up

Industry: Biotech


Ranked

of 489

in industry

Filter BPTH News Items

BPTH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest BPTH News From Around the Web

Below are the latest news stories about Bio-Path Holdings Inc that investors may wish to consider to help them evaluate BPTH as an investment opportunity.

Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

HOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright BioConnect 2022 Virtual Conference made available on Monday, January 10, 2022 at 7:00 a.m. ET. An audio webcast of the pr

Yahoo | January 5, 2022

Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting

Preliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML PatientsHOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces a poster highlighting the safety and preliminary efficacy data of its Phase 2 study of prexigebersen (BP1001) was presented at the 2021 American So

Yahoo | December 13, 2021

Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | December 6, 2021

Brokerages Anticipate Bio-Path Holdings, Inc. (NASDAQ:BPTH) to Announce -$0.32 EPS

Analysts expect Bio-Path Holdings, Inc. (NASDAQ:BPTH) to post earnings of ($0.32) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Bio-Paths earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.35). Bio-Path posted earnings of ($0.57) per share during the same quarter last year, []

Transcript Daily | November 22, 2021

Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q3 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | November 12, 2021

Bio-Path Holdings Reports Third Quarter 2021 Financial Results

No summary available.

Bio-Path Holdings | November 11, 2021

Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021

HOUSTON, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 12, 2021 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2021 and to provide a business overview.

Intrado Digital Media | November 5, 2021

Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting

HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 11-14, 2021 in Atlanta, GA. In addition, ASH abstracts will appear in the November supplemental issue of Blood.

Intrado Digital Media | November 4, 2021

Zacks: Analysts Expect Bio-Path Holdings, Inc. (NASDAQ:BPTH) to Announce -$0.33 EPS

Wall Street analysts expect Bio-Path Holdings, Inc. (NASDAQ:BPTH) to report earnings of ($0.33) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Bio-Paths earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.36). Bio-Path reported earnings of ($0.80) per []

Dakota Financial News | November 3, 2021

-$0.33 Earnings Per Share Expected for Bio-Path Holdings, Inc. (NASDAQ:BPTH) This Quarter

Wall Street analysts expect that Bio-Path Holdings, Inc. (NASDAQ:BPTH) will announce earnings per share (EPS) of ($0.33) for the current quarter, according to Zacks. Zero analysts have issued estimates for Bio-Paths earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.36). Bio-Path posted earnings of ($0.80) per share during the same quarter last []

Transcript Daily | October 27, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5939 seconds.